TriNetX, a health research firm based in Cambridge, Mass., Today announced it raised $ 40 million in underwritten D-Series funds led by the Merck Global Health Innovation Fund, along with participation of new investors, Mitsui, Itochu and Itochu, the investment arm Technology Ventures. , alongside existing investors MPM Capital, F2 Ventures and Deerfield Management. This brings the total of TriNetX to $ 102 million. This money will fuel its international expansion into Europe, Asia and South America and help it further develop its digital clinical trial and AI technology.
According to TrioX, CEO Gadi Lachman, the injection of funds comes as TriNetX's business figure exceeds eight figures with a 200% growth over the previous year. He currently supports electronic medical records and genomic analyzes of more than 300 million patients from "hundreds" of health care facilities in 17 countries, including the United States, the United Kingdom, the United States, and the United States. Germany, Italy, Japan, Singapore, India and Brazil. Novartis, Sanofi, Pfizer, etc.
"The landscape of clinical research is changing and TriNetX is leading the crisis as industry increasingly shifts to exploiting data-driven information to inform clinical research and surveillance." market, "said Lachman. "We have created the only real evidence ecosystem that brings together data, analysis and a community of researchers to facilitate the design of randomized or pragmatic clinical trials and to support observational studies, whether they are retrospective or prospective, controlled or longitudinal. "
TriNetX – Original Idea of David Fusari, Former Senior Architect of Microsoft's Healthcare Solutions Group – Delivers a Trio of Cloud-Based, HIPAA and GDPR-Compliant Subscription Services to Streamline the Medical Research Process : TriNetX Research, TriNetX Download and TriNetX Analyze. Together, they include a suite of test design, cohort analysis, and site selection tools that allow users to query and download data from within the framework of the project. a claims database of "billions" of aggregated clinical facts, including exit summaries, laboratory analyzes, across therapeutic areas, and more.
In addition, TriNetX leverages the natural language processing technology of the German company Averbis to extract unstructured data from clinician notes for patients, which it then maps to standardized clinical terminology to fill the gaps in the records. incomplete medical (Customers who use it download documents and their associated metadata into an on-premises target directory of TriNetX appliance hardware.) This is in addition to a recently launched algorithm that can separate the line. treatment of patients in chemotherapy from models of registers and tumoral pathologies. reports.
In the end, the goal is to reduce barriers to entry into clinical research. With TriNetX, researchers can perform tasks such as tracking treatments received by patients to determine when (and why) they have opted for new treatments, or apply customized statistical models to generate predictions without direct access to clinical data. .
"Real-world data is important for driving clinical trials, drug research and therapeutic discoveries today," said Joe Volpe, Vice President and General Manager of the Innovation Fund. in the health of Merck Global. "TriNetX enables a global industrial exchange and frees up data with the potential to quickly provide answers to difficult questions. With TriNetX, it often took days or even weeks to figure out what had been done before – so we're excited to be part of this fundraising effort to develop and expand TriNetX's offerings. "